Pharmacist Digest

Clinical trial begins of lung cancer immunotherapeutic

pharmaphorum

JANUARY 18, 2022

Cancer Research UK’s Centre for Drug Development, working with the Ludwig Institute for Cancer Research and Vaccitech, has begun a phase I/IIa clinical trial of a new lung cancer vaccine. Nigel Blackburn, director of cancer research UK’s Centre for Drug Development, said in a statement.

Immunity

Immunity Immunization Vaccines Drug Development

STAT+: This chemist’s last startup sold for $4 billion. Now investors have poured $173 million into her next act

STAT

FEBRUARY 29, 2024

BlossomHill is preparing to start human clinical studies of potential medicines that could someday treat blood cancer and lung cancer. Among her targets: a competitor to AstraZeneca’s Tagrisso, one of the best-selling cancer pills on the market.

STAT+: Novocure’s electric fields device prolongs survival in lung cancer, but doubts remain

STAT

JUNE 6, 2023

CHICAGO — A medical device made by Novocure that creates electric fields in the lungs via wearable skin patches extended the survival of patients with lung cancer in a clinical trial, researchers reported Tuesday. Delivering additional sales, however, could be a significant challenge.

Chemotherapy

Chemotherapy Immunity Immunization

STAT+: Mirati wins FDA approval for KRAS-blocking lung cancer drug, but blockbuster sales hopes have dimmed

STAT

DECEMBER 12, 2022

The Food and Drug Administration on Monday approved a second KRAS-blocking treatment for advanced lung cancer. However, hopes the drug might reach a large swath of patients — and grow into a commercial blockbuster for its maker Mirati Therapeutics — have dimmed in the wake of underwhelming clinical trial results.

STAT+: Cancer drug shortages widen disparities between big systems and small

STAT

SEPTEMBER 25, 2023

For months, oncologist Kristen Rice found herself scrambling for cisplatin and carboplatin, two key chemotherapies used for many different cancers including ovarian, bladder, and lung cancer. Pharmacy technicians would order more drugs each day to keep the clinic running until, one day, they couldn’t.

Pharmacy Technician

Pharmacy Technician Chemotherapy Hospitals

STAT+: FDA finds ‘potential systemic bias’ in Amgen’s KRAS drug trial ahead of advisory meeting

STAT

OCTOBER 3, 2023

A follow-up study of a first-of-its-kind cancer treatment may reflect systemic biases, the Food and Drug Administration said ahead of an advisory committee meeting Thursday to determine whether the drug should remain on the market. Now, the drug’s manufacturer, Amgen, needs to prove it works.

STAT+: The woman behind AstraZeneca’s cancer winning streak

STAT

JUNE 6, 2023

When given after surgery to the right lung cancer patients, selected using genetic tests, it cut the death rate in half. On Sunday, thousands of oncologists applauded after researchers presented data on AstraZeneca’s Tagrisso. Benjamin J. “It was a great day,” she said.

Drug Development

STAT+: What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s surprising rise

STAT

JANUARY 25, 2024

Gilead needs Arcellx more than ever The clinical trial setback for Trodelvy in non-small cell lung cancer reported by Gilead Sciences on Monday was another dose of bad news for the company’s oncology business.

STAT+: Data likely support approval of Amgen’s KRAS-targeted drug, but still come with disappointments

STAT

SEPTEMBER 12, 2022

Clinical trial results reported Monday by Amgen may be enough to confirm the U.S. approval of its KRAS-targeting lung cancer drug called Lumakras. But the new data also show lung cancer patients are not benefiting from Lumakras as much as previously hoped, and liver toxicity remains a safety concern.

Chemotherapy

STAT+: AstraZeneca shares fall after lung cancer drug underwhelms in trial

STAT

JULY 3, 2023

LONDON — AstraZeneca said on Monday that a new lung cancer treatment outperformed standard-of-care chemotherapy in a trial, but investors found the results less impressive than anticipated, sending company shares down in early trading. But investors had been hoping for a clearer signal of benefit.

Chemotherapy

Chemotherapy Drug Development

GSK enters exclusive license agreement with Hansoh for HS-20093

LifeProNow

DECEMBER 22, 2023

Under the agreement, GSK will obtain exclusive worldwide rights (excluding China’s mainland, Hong Kong, Macau, and Taiwan) to progress clinical development and commercialisation of HS-20093. In October 2023, GSK and Hansoh entered into an agreement for HS-20089, a B7-H4 targeted ADC currently in phase II clinical trials in China.

AST-001 by Ascentawits Pharmaceuticals for Non-Small Cell Lung Cancer: Likelihood of Approval

Pharmaceutical Technology

APRIL 22, 2024

AST-001 is under clinical development by Ascentawits Pharmaceuticals and currently in Phase II for Non-Small Cell Lung Cancer.

AstraZeneca shares results for Imfinzi in phase 3 trial for small cell lung cancer

Pharmafile

APRIL 5, 2024

AstraZeneca has announced positive high-level results from the phase 3 ADRIATIC trial, which demonstrated that Imfinzi (durvalumab) had a statistically significant and clinically meaningful improvement in the dual primary endpoints of overall survival (OS) and progression-free survival (PFS) in patients with limited-stage small cell lung cancer (LS-SCLC) (..)

STAT+: Gilead, Arcus anti-TIGIT drug reduces risk of lung cancer progression in mid-stage study

STAT

DECEMBER 19, 2022

Gilead Sciences and Arcus Biosciences said Monday that an experimental cancer immunotherapy directed against a target called TIGIT reduced the risk of tumor progression or death by 45% in a mid-stage clinical trial involving patients with lung cancer.

STAT+: An accidental data release by Roche boosts some hopes for anti-TIGIT cancer immunotherapies

STAT

AUGUST 23, 2023

Roche confirmed it accidentally released interim data from a closely watched clinical trial testing whether blocking that target — a protein on T cells known as TIGIT — can enable non-small lung cancer patients to live longer than standard immunotherapy alone. In the wee hours of Wednesday morning, it got another.

EGFR inhibitor could provide major advance in lung cancer

European Pharmaceutical Review

FEBRUARY 21, 2024

Small molecule treatment TAGRISSO ® (osimertinib) demonstrated a “statistically significant and highly clinically meaningful improvement” in progression-free survival (PFS) for Stage III lung cancer patients, AstraZeneca has confirmed. This was established from positive high-level results seen in the LAURA Phase III trial.

Chemotherapy

STAT+: Keytruda’s benefits, a breast cancer win, the ‘dom-zim doublet’: Weekend wrap-up from ASCO

STAT

JUNE 5, 2023

CHICAGO — The annual meeting of the American Society of Clinical Oncology is back in full force here, with plenaries and poster sessions as packed as before the pandemic. Hopeful results were presented for patients with glioma, a type of brain cancer that tends to strike people in middle age.

Drug Pricing

Drug Pricing Drug Development

Roche presents five-year survival outcomes for Tecentriq plus chemotherapy in ES-SCLC

Express Pharma

SEPTEMBER 10, 2023

Results presented from the Phase III IMpower133 study and extension trial IMbrella A, show Roche’s Tecentriq (atezolizumab), in combination with chemotherapy, demonstrates a potential long-term overall survival (OS) benefit as first-line treatment for extensive-stage small cell lung cancer (ES-SCLC). 0.91; p=0.0069). Front Oncol.

Chemotherapy

STAT+: ‘Extraordinary’ survival data for lung cancer patients is seen as boost for AstraZeneca drug

STAT

JUNE 4, 2023

CHICAGO – Giving the AstraZeneca drug Tagrisso to patients with non-small cell lung cancer who have had their tumors removed reduced the risk of death by 51%, researchers said Sunday. Put another way, that would mean that about one in 10 patients who received the drug would live another five years.

Drug Development

AstraZeneca’s Tagrisso to lead lung cancer small molecule market with over $7 bn sales by 2029: GlobalData

Express Pharma

OCTOBER 10, 2023

In the ever-evolving landscape of oncology, small-molecule drugs are carving a significant niche in lung cancer treatment. This approval marked a significant advancement in the treatment of metastatic EGFR T790M mutation-positive non-small cell lung cancer (NSCLC).

STAT+: ASCO showcased the payoff for new cancer medicines: longer lives

STAT

JUNE 7, 2023

The biggest meeting in cancer research — and, really, one of the biggest annual conferences for the pharmaceutical industry as a whole — has drawn to a close. What did we learn from this year’s annual meeting of the American Society of Clinical Oncology? CHICAGO — Well, that’s a wrap.

Drug Development

New Amgen immunotherapy could treat common solid tumour

European Pharmaceutical Review

NOVEMBER 24, 2023

Amgen’s new immunotherapeutic agent Tarlatamab has been shown in a Phase II trial to provide sustained anti-tumour activity in 40 percent of the small cell lung cancer patients. The international DeLLphi-301study was investigated as a new anti-cancer treatment option for patients previously considered to be beyond treatment.

Hospitals

Hospitals Dosage

Prothea debuts with $13m to develop cancer diagnostics and treatment

Pharmaceutical Technology

APRIL 9, 2024

Prothea plans to use the funds to start clinical trial for cancer imaging, biopsy and laser ablation treatment in lung cancer patients.

Cell therapy approach harnesses the immune system in a different way to stop cancer

World Pharma News

MARCH 19, 2024

A new cancer treatment that uses a person’s own immune cells has been approved by the U.S. Food and Drug Administration (FDA) for treating the most dangerous type of skin cancer. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James).

Immunity

Immunity Immunization Hospitals

SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Squamous Non-Small Cell Lung Cancer: Likelihood of Approval

Pharmaceutical Technology

APRIL 18, 2024

SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Squamous Non-Small Cell Lung Cancer.

CStone Pharma shares jump after academic recognition of its lung-cancer treatment

Outsourcing Pharma

JUNE 19, 2023

CStone Pharmaceuticals' shares have risen after academic journal Nature Cancer published the clinical study results of its lung-cancer treatment sugemalimab.

Research predicts 2029 small molecule oncology market leaders

European Pharmaceutical Review

OCTOBER 12, 2023

Strong demand for small molecules as treatment for non-small cell lung cancer (NSCLC) in the eight major markets means that the small molecule treatment market for the disease is expected to reach over $15 billion by 2029. As the current landscape for lung cancer therapeutics stands, 39 small molecules have been commercialised.

AFNT-211 by Affini-T Therapeutics for Non-Small Cell Lung Cancer: Likelihood of Approval

Pharmaceutical Technology

APRIL 22, 2024

AFNT-211 is under clinical development by Affini-T Therapeutics and currently in Phase II for Non-Small Cell Lung Cancer.

GH-21 by HUYA Bioscience International for Non-Small Cell Lung Cancer: Likelihood of Approval

Pharmaceutical Technology

APRIL 19, 2024

GH-21 is under clinical development by HUYA Bioscience International and currently in Phase I for Non-Small Cell Lung Cancer.

DF-4101 by AbbVie for Non-Small Cell Lung Cancer: Likelihood of Approval

Pharmaceutical Technology

APRIL 19, 2024

DF-4101 is under clinical development by AbbVie and currently in Phase I for Non-Small Cell Lung Cancer.

Sanofi stops development of lung cancer drug

European Pharmaceutical Review

DECEMBER 22, 2023

French pharmaceutical giant Sanofi announced that it is ending the development programme evaluating tusamitamab ravtansine as a monotherapy for certain patients with metastatic non-squamous, non-small cell lung cancer (NSCLC). It may be overexpressed in many different cancer types.

Labelling

Genentech shares phase 3 results for ALK-positive early-stage lung cancer treatment

Pharmafile

SEPTEMBER 1, 2023

Roche’s Genentech has announced that the phase 3 ALINA trial assessing Alecensa, compared with platinum-based chemotherapy for the treatment of early-stage anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC), met its primary endpoint of disease-free survival (DFS).

Chemotherapy

Chemo-free regimen demonstrates efficacy in NSCLC

European Pharmaceutical Review

SEPTEMBER 29, 2023

Janssen Pharmaceutical Companies of Johnson & Johnson’s Phase III MARIPOSA study is the first to show a clinically meaningful benefit in a chemotherapy-free regimen compared to the small molecule treatment TAGRISSO ® ( osimertinib ).

Pharmaceutical Companies

Pharmaceutical Companies Pharmaceutical Companies Chemotherapy Immunity

Deal activity in pharma industry in April 2024

Express Pharma

MAY 8, 2024

Vertex Pharmaceuticals Inc, a biotechnology company, to acquire Alpine Immune Sciences Inc, a clinical stage biotechnology company, for a consideration of approximately $4.9 billion; Genmab AS, a biotechnology company to acquire ProfoundBio, a clinical-stage biotechnology company, for $1.8 billion in cash. billion in cash.

Immunity

Immunity Immunization

AstraZeneca backs AI-based lung cancer diagnosis pilot in UK

pharmaphorum

JANUARY 17, 2023

and a clinical group in the UK to test an artificial intelligence-powered technology to help radiologists detecting lung cancer in chest X-rays. Greater Manchester has been selected as the site for the trial, as rates of lung cancer there are among the highest in the UK, said the partners. ” AZ and Qure.ai

Novel vaccine delivers significant survival in lung cancer trial

European Pharmaceutical Review

SEPTEMBER 12, 2023

A T-cell epitope cancer vaccine significantly improved overall survival in non-small cell lung cancer (NSCLC) compared to chemotherapy, Phase III data published in Annals of Oncology has shown. The findings also demonstrated a clinically meaningful benefit in median overall survival of 3.6 percent versus 27.5

Vaccines

Vaccines Chemotherapy Immunity Immunization

NICE recommends new treatment for EGFR-positive lung cancer

European Pharmaceutical Review

NOVEMBER 17, 2022

Final draft guidance published by the National Institute for Health and Care Excellence (NICE), recommends Mobocertinib (Exkivity), a new therapy that helps slow cancer growth in adults with epidermal growth factor receptor ( EGFR ) exon 20+ non-small-cell lung cancer (NSCLC), who have already received platinum-based chemotherapy.

Chemotherapy

Air of optimism surrounds lung cancer vaccine

Pharma Times

JANUARY 18, 2022

Cancer Research UK announces clinical trial for most common type of lung cancer

Vaccines

Roche subcutaneous cancer immunotherapy granted MHRA approval

European Pharmaceutical Review

AUGUST 29, 2023

The Medicines and Healthcare Products Regulatory Agency (MHRA) has authorised the first subcutaneous formulation of an anti-PD-(L)1 cancer immunotherapy to be made available to patients in Great Britain. Tecentriq SC will be available on the NHS in Great Britain for certain types of lung, bladder, breast, and liver cancer.

Immunity

Immunity Immunization

US FDA grants orphan drug designation to Biostar Pharma’s utidelone

Pharmaceutical Business Review

APRIL 1, 2024

Utidelone’s unique properties allow it to cross the blood-brain barrier (BBB), a capability supported by both preclinical and clinical studies. Last year, the company said it was ready to advance UTD1 in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC), following approval from the FDA for the study.

SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Squamous Non-Small Cell Lung Cancer: Likelihood of Approval

Pharmaceutical Technology

APRIL 18, 2024

SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Squamous Non-Small Cell Lung Cancer.

SN Bioscience’s SNB-101 received FDA orphan drug designation

Pharmaceutical Business Review

FEBRUARY 29, 2024

This development is based on pre-clinical findings of the drug in treating pancreatic cancer, a condition with a notably low five-year survival rate and limited treatment options. Animal studies suggest its effectiveness against lung, pancreatic, and stomach cancers, which were not previously indicated.

Drug Development

Digital health collaboration to trial AI-powered X-rays for lung cancer detection

Pharma Times

DECEMBER 18, 2023

Earlier diagnosis could increase patient survival rates by five years or more The University of Glasgow has announced that an artificial intelligence (AI)-enhanced chest X-ray reporting solution has begun trials in NHS Greater Glasgow and Clyde (NHSGGC) for early detection of lung cancer. The Qure.ai

Hospitals

Clinical Trial of Keytruda and Lynparza Combination Fails to Meet Primary Endpoint for Treatment of Metastatic Nonsquamous Non-Small Cell Lung Cancer

PharmExec

MARCH 22, 2024

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Clinical trial begins of lung cancer immunotherapeutic

STAT+: This chemist’s last startup sold for $4 billion. Now investors have poured $173 million into her next act

Trending Sources

STAT+: Novocure’s electric fields device prolongs survival in lung cancer, but doubts remain

STAT+: Mirati wins FDA approval for KRAS-blocking lung cancer drug, but blockbuster sales hopes have dimmed

STAT+: Cancer drug shortages widen disparities between big systems and small

STAT+: FDA finds ‘potential systemic bias’ in Amgen’s KRAS drug trial ahead of advisory meeting

STAT+: The woman behind AstraZeneca’s cancer winning streak

STAT+: What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s surprising rise

STAT+: Data likely support approval of Amgen’s KRAS-targeted drug, but still come with disappointments

STAT+: AstraZeneca shares fall after lung cancer drug underwhelms in trial

GSK enters exclusive license agreement with Hansoh for HS-20093

AST-001 by Ascentawits Pharmaceuticals for Non-Small Cell Lung Cancer: Likelihood of Approval

AstraZeneca shares results for Imfinzi in phase 3 trial for small cell lung cancer

STAT+: Gilead, Arcus anti-TIGIT drug reduces risk of lung cancer progression in mid-stage study

STAT+: An accidental data release by Roche boosts some hopes for anti-TIGIT cancer immunotherapies

EGFR inhibitor could provide major advance in lung cancer

STAT+: Keytruda’s benefits, a breast cancer win, the ‘dom-zim doublet’: Weekend wrap-up from ASCO

Roche presents five-year survival outcomes for Tecentriq plus chemotherapy in ES-SCLC

STAT+: ‘Extraordinary’ survival data for lung cancer patients is seen as boost for AstraZeneca drug

AstraZeneca’s Tagrisso to lead lung cancer small molecule market with over $7 bn sales by 2029: GlobalData

STAT+: ASCO showcased the payoff for new cancer medicines: longer lives

New Amgen immunotherapy could treat common solid tumour

Prothea debuts with $13m to develop cancer diagnostics and treatment

Cell therapy approach harnesses the immune system in a different way to stop cancer

SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Squamous Non-Small Cell Lung Cancer: Likelihood of Approval

CStone Pharma shares jump after academic recognition of its lung-cancer treatment

Research predicts 2029 small molecule oncology market leaders

AFNT-211 by Affini-T Therapeutics for Non-Small Cell Lung Cancer: Likelihood of Approval

GH-21 by HUYA Bioscience International for Non-Small Cell Lung Cancer: Likelihood of Approval

DF-4101 by AbbVie for Non-Small Cell Lung Cancer: Likelihood of Approval

Sanofi stops development of lung cancer drug

Genentech shares phase 3 results for ALK-positive early-stage lung cancer treatment

Chemo-free regimen demonstrates efficacy in NSCLC

Deal activity in pharma industry in April 2024

AstraZeneca backs AI-based lung cancer diagnosis pilot in UK

Novel vaccine delivers significant survival in lung cancer trial

NICE recommends new treatment for EGFR-positive lung cancer

Air of optimism surrounds lung cancer vaccine

Roche subcutaneous cancer immunotherapy granted MHRA approval

US FDA grants orphan drug designation to Biostar Pharma’s utidelone

SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Squamous Non-Small Cell Lung Cancer: Likelihood of Approval

SN Bioscience’s SNB-101 received FDA orphan drug designation

Digital health collaboration to trial AI-powered X-rays for lung cancer detection

Clinical Trial of Keytruda and Lynparza Combination Fails to Meet Primary Endpoint for Treatment of Metastatic Nonsquamous Non-Small Cell Lung Cancer

Stay Connected